Developing a new therapeutic pipeline to treat metabolic diseases that present global health challenges.
Now advancing our first-in-class drug candidate for metabolic disease.
The Challenge of Patients’ Unmet Clinical Needs
Senseion Therapeutics is a preclinical-stage pharmaceutical company developing new medicines to treat metabolic diseases that present global health challenges—specifically those associated with chloride ion-channel diseases.
First in our pipeline and under development now is a small molecule therapeutic, SN-40X, to treat metabolic disease.
